Considering low expression levels of SGLT2 (Slc5a2) in the liver and cellular component of the liver, CANA is unlikely to have direct effects on these cells to attenuate either hepatic steatosis or the subsequent pathologic changes. This evidence concerns the gene SLC5A2 and Hepatic steatosis.